HGK promotes metastatic dissemination in prostate cancer

Sara Garcia-Garcia1,5, Maria Rodrigo-Faus1,5, Noelia Fonseca1, Sara Manzano1-2, Balázs Győrffy3,4, Alberto Ocaña2, Paloma Bragado1,2, Almudena Porras3,4 & Alvaro Gutierrez-Uzquiza1,2*

Metastasis is the process of cancer cell dissemination from primary tumors to different organs being the bone the preferred site for metastatic homing of prostate cancer (PCa) cells. Prostate tumorigenesis is a multi-stage process that ultimately tends to advance to become metastatic PCa. Once PCa patients develop skeletal metastases, they eventually succumb to the disease. Therefore, it is imperative to identify essential molecular drivers of this process to develop new therapeutic alternatives for the treatment of this devastating disease. Here, we have identified MAP4K4 as a relevant gene for metastasis in PCa. Our work shows that genetic deletion of MAP4K4 or pharmacological inhibition of its encoded kinase, HGK, inhibits metastatic PCa cells migration and clonogenic properties. Hence, MAP4K4 might promote metastasis and tumor growth. Mechanistically, our results indicate that HGK depleted cells exhibit profound differences in F-actin organization, increasing cell spreading and focal adhesion stability. Additionally, HGK depleted cells fails to respond to TNF-α stimulation and chemoattractant action. Moreover, here we show that HGK upregulation in PCa samples from TCGA and other databases correlates with a poor prognosis of the disease. Hence, we suggest that it could be used as prognostic biomarker to predict the appearance of an aggressive phenotype of PCa tumors and ultimately, the appearance of metastasis. In summary, our results highlight an essential role for HGK in the dissemination of PCa cells and its potential use as prognostic biomarker.

According to the World Health Organisation, Prostate cancer (PCa) is the second most frequent cancer among men and the fifth leading cause of all deaths1. Although most PCa patients have a high survival rate, the 5-year survival rate for patients who develop Castration-Resistant Prostate Cancer (CRPC) or metastasis is 29%. CRPC is the result of a prostate tumorigenesis process where low-grade prostatic intraepithelial neoplasia (PINs) progresses to an aggressive adenocarcinoma that does not respond to hormone deprivation therapy. During this process the tumor can spread to distant organs becoming a metastatic disease2. In fact, around 80% of CRPC patients will evolve to metastatic CRPC1. Indeed, 6% of men diagnosed with PCa will develop metastatic CRPC for which effective treatment has not yet been developed. Transition to CRPC is the main, but not the only, source of metastatic dissemination, since 3% of PCa patients will have metastatic dissemination at the time of diagnosis2.

Metastasis is the process that allows cancer cell dissemination from the primary tumor to other organs in the body and their seeding in this new niche, generating new tumors. The vast majority of PCa metastases are found in the perivascular niches of the bone marrow sinusoids, which seems to be the preferred metastatic niche of PCa tumor cells3. The molecular mechanisms beneath cell migration movements of tumoral cells are complex, heterogeneous and poorly understood, limiting the development of effective therapies. Nonetheless, it is accepted that the occurrence of this process involves rearrangements of cell cytoskeleton and altered signalling of cell adhesion receptors leading to improvement of motility and invasive properties in tumor cells4. Therefore, the inhibition of any of these processes has the potential to prevent the metastatic event.

Protein kinases represent a promising group to explore due to its ability to regulate signaling pathways involved in cell motility and its susceptibility of being inhibited by chemical compounds. Several studies have associated the aberrant expression of these proteins with PCa metastasis5. In an interesting study, Falteimer et al., identified 20 kinases with metastatic promoting ability4, including several members of the MAPK superfamily.

1Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid, Ciudad Universitaria, Madrid, Spain. 2Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdiSSC), Madrid, Spain. 3Department of Bioinformatics and 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary. 4TTK Cancer Biomarker Research Group, Budapest, Hungary. 5These authors contributed equally: Sara Garcia-Garcia and Maria Rodrigo-Faus—email: alguuz@ucm.es
HGK is a member of the STE20 family and a component of the MAPKs pathway. It is a serine/threonine kinase reported to be activated by TNF-α as an upstream regulator of the stress-induced c-jun-N-terminal (JNK) signaling pathway and activating transcription factor 2 (ATF2)\(^6\). Emerging evidence suggests that HGK regulates many cellular functions that control cell motility, proliferation, wound healing and stress\(^6\). In normal tissues, higher levels of MAP4K4 (gene encoding HGK protein) mRNA are found in brain and in testis, and notably, it is markedly expressed in 40 out of 60 cancer cells lines derived from a variety of tissues\(^7\). Previous studies have shown associations between HGK levels and cancer. For example, HGK protein levels were elevated in lung adenocarcinoma\(^8\), pancreatic cancer\(^9\), hepatocellular carcinoma\(^10\), kidney tumors and brain tumors\(^1\). In the same line, upregulation of its expression was associated with a poor patient prognosis in colorectal cancer\(^11\), HCC\(^10\), pancreatic ductal adenocarcinoma\(^12\) and lung adenocarcinoma\(^13\).

Interestingly, high levels of MAP4K4 expression and/or protein levels augmented proliferation and invasion in ovarian cancer\(^14\), medulloblastoma\(^15\), and glioblastoma\(^16\). HGK is also involved in actin dynamic regulation and has been shown to facilitate migration in keratinocytes\(^17\). Different hypothesis have been proposed to explain the molecular mechanisms by which HGK may regulate cancer cells disseminative properties; such as the upregulation of the MYC oncogene\(^18\), the MAPKs\(^8\) or the induction of the epithelial to mesenchymal transition in glioblastoma\(^19\). However, the proposed molecular mechanisms are not consistent across the different studies and none of them consider its role as an actin dynamic regulator.

Understanding the molecular mechanisms and signaling pathways that drive migration and invasion in PCa may lead not only to find better biomarkers of tumor status, but also novel therapeutic targets for the treatment of this disease. Due to the high number of functions that this protein is able to coordinate, we hypothesized that HGK functions in PCa cells as a hub, integrating growth factor and stress signals in a way that could promote motility and invasiveness. In order to test this hypothesis and shed some light into the molecular mechanisms used by HGK to regulate the metastatic process of prostate cancer, we have analyzed the role of HGK in PCa cells by applying the novel CRISPR/Cas9 knock out approach.

**Material and methods**

**Patient cohort and RNAseq analysis.** Publicly available level 3 normalized RNAseqV2 data of 537 prostate adenocarcinoma (PRAD) patients from TCGA was downloaded from FIREBROWSE (http://firebrowse.org/) and CICbioGUNE (https://www.cicbiogune.es/). Samples were classified in three groups: solid normal tissue, primary tumor and metastasis. U-Mann–Whitney statistical test was applied to check whether there were differences in MAP4K4 gene expression between the three groups of patients.

**Cells culture maintenance and reagents.** LnCaP and 22rv1 PCa cell lines obtained from ATCC (Manassas, VA, USA) were kindly donated by Dr. Guillermo Velasco. PC3 and DU145 cell lines were obtained from ATCC (Manassas, VA, USA). LnCaP, 22rv1 and DU145 were cultured in RPMI 10% FBS. PC3 were cultured in RPMI/F12 10% FBS. HEK-293 T cells cultured in 10% FBS DMEM medium were used for virus amplification. To trigger HGK signaling cells were treated with TNF-α (20 ng/mL; R&D, Minneapolis, MN, USA). The chemical inhibitor used to inhibit HGK was PF 06,260,933 (1–10 µM; Sigma, PZ0272).

**RNA Isolation, Reverse Transcription-PCR, and q-PCR analysis.** Total RNA was isolated from the cells using RNeasy Mini Kit (QIAGEN, Hilden, Germany). Reverse transcription PCR (RT-PCR) was performed using Supercript IV Reverse Transcriptase (ThermoFisher, Waltham, MA, USA). Triplicate samples with their corresponding controls were assessed by qPCR, performed at the Universidad Complutense de Madrid (UCM) Genetic and Genomic facility. Melting curves of all qPCR reaction were closely monitored to avoid non-specific SYBR green signals. Gene fold changes were determined by the 2-ΔΔCt algorithm\(^20\). All primer sequences used correspond ing controls were assessed by qPCR, performed at the Universidad Complutense de Madrid (UCM) Genetic and Genomic facility. Melting curves of all qPCR reaction were closely monitored to avoid non-specific SYBR green signals. Gene fold changes were determined by the 2-ΔΔCt algorithm\(^20\). All primer sequences used are listed in supplementary section. GAPDH was used as reference gene to normalize the 2-ΔΔCt based assessments and LNCaP was used to normalize the expression between cell lines.

**Protein expression.** Cells were lysed in RIPA buffer with protease and phosphatase inhibitors (PMSF 1 mM, aprotinin 10 µg/ml, leupeptin 10 µg/ml, Na3VO4 1 mM and NaF 20 mM). Protein concentrations were measured using a standard curve prepared with known concentrations of BSA. Samples were prepared using 4×10⁵ CFU of bacteria. SDS-PAGE gels were transferred to PVDF membranes, blocked with 5% fat milk in Tween 20 and incubated with the following primary antibodies 1:1000 diluted in 5% BSA TTBS overnight. Actin CST-#3700, Tubulin CST-#3873, HGK CST-#5146, P-p38 CST-#9211, P-FAK CST-#3283 and P-SAPK/JNK CST-#9251 were used as primary antibodies. Membranes were washed with TTBS and incubated with secondary anti-mouse IgG SCT sc-#516102 or Anti-rabbit IgG SCT sc-#237 antibodies conjugated with HRP in 5% BSA TTBS for 1 h (1:5000). HRP luminescence was stimulated using Clarity Western ECL Substrate (Bio-Rad) and detected with VWR image view station. ImageJ was used for quantification.

**CRISPR/Cas9 depletion cells production.** Lenti-Cas9 Viral production was performed in 4×10⁵ HEK-293 T cells seeded in 10 cm tissue culture plates coated with 0.2% gelatine (skin porcine). A mixture of the 3 transfection plasmids (Packaging and enveloping plasmids psPAX2 and pMD2.VSVg (addgene#12260; addgene#8454)) together with lentiCas9-Blast plasmid addgene#52962) was prepared and mixed with polyethyle neimine (PEI) in a 1:6 ratio and transferred to the HEK-293 T cells. After 72 h, the medium was collected, centrifugated at 5000 rpm for 5 min, and filtered with a 0.45 µm polycarbonate filter (Cultek, #15431231). PC3 cells were transduced with Lenti-Cas9 expressing lentivirus to induce the expression of Cas9 in presence of 8 µg/ml of polybrene. 48 h later, blasticidin selection (10 µg/ml) was performed for 5 days. Individual clones were
expanded and the Cas9 presence was verified by Western-blot using Cas9 anti-mouse IgG and proliferation/migration test were performed to ensure no clonal effect was present (data not shown). Specific MAP4K4 gRNAs were annealed and cloned in plasmid leniGuide-puro plasmid (Addgene #52963) using BsmBI cloning site (Forward seq 5′-CACCGGTTGGTCATGATCTCG-3′ and reverse AAACCGAGGAATGATGACGAA CTG). Sanger sequencing confirmed the gRNA insertion and plasmid sequence. Viral productions to deliver gRNA in cells was performed as above using packaging and enveloping plasmids psPAX2 and pMD2.VSVG (Addgene#12260; addgene#8454) together with plenti-Guide-puro (Addgene#52963) containing gRNAs or NTC sequence (Forward 5′-CACCCGGCTAGACCTGTTTA-3′ and reverse AAAC TAAACCGAGGTGCCTACGCGC-3′). PC3-Cas9 were transduced with lentivirus (MAP4K4-1) in presence of polybrene (8 µg/ml) to knock down the expression of MAP4K4. After 2 days, puromycin selection (1 µg/µl) was added for 6 days. Clones were subcloned in a 96 multwell plate and DNA was extracted using the Proteinase K method. Targeted region was PCR amplified, and sequence for the detection of indels. Presence of indels was used as inclusion criteria for HGK protein expression analysis assessed by Western-blot using HGK antibody followed by a secondary antibody conjugated to HRP.

**Migration assays.** Wound healing-like migration was assessed by scratch assay using cell plates with a confluence of 100%. The cells were serum-deprived for 6 h before scratch was made with a pipette tip. Subsequently, they were kept in culture medium without serum and photographs were taken at 24 h with a phase contrast microscope, which were processed using the TScratch software.

For evaluation of migration through a transwell, the upper chamber with a 8 µm filter was filled with medium 0% FBS containing 25 000 cells, while the lower chamber was filled with 5% FBS medium or TNF-α (20 ng/ml). After 18 h, migration of the cells through the membrane was examined by fixing with paraformaldehyde 4% for 20 min and staining with crystal violet in aqueous solution (0.2%). Then, extra stain was removed, and cells were visualized with Eclipse TE300 Nikon microscope and photographed with digital DS-U2 camera. ImageJ was used to count the cells that traversed the membrane.

**Cell cycle analysis.** Cells maintained in the indicated conditions were trypsinized and centrifuged at 2500 rpm 5 min at 4 °C, fixed with cold ethanol (70%) and washed with PBS. Cells resuspended in PBS were incubated 30 min with RNase (0.1 µg/ml) at 37 °C. Then, propidium iodide (0.05 µg/µl) was added and cell cycle analysed by flow cytometry. Modfit software was used to determine the percentage of cells in the different phases.

**Anchorage-dependent and -independent growth assays.** Anchorage-dependent growth was evaluated by seeding 300 cells per 6 multi-well plate with RPMI/F12 10% FBS. After 8 days, the colonies were fixed and stained with crystal violet (0.2%, in 2% ethanol), counting the number of colonies with the ImageJ software. Anchorage independent growth was evaluated by preparing 24 Multitissue plates with 0.5 ml of a mixture 1:1 of agar 1% and RPMI/F12 10% FBS. 3000 cells were seeded per 24 multiwell with RPMI/F12 10% FBS mixed 1:1 with agar 0,7%. Each sample was analysed per triplicate. Number of colonies were counted manually.

**Sprouting assay.** Multicellular spheroids for the sprouting assay were initiated by seeding 625 PC3-NTC cell or HGK deleted PC3-HGK-KO-1 or PC3-HGK-KO-2 in several 25 µl hanging drops with RPMI/F12 medium. Under these conditions, cells aggregate into a single spheroid by 3–4 days. Spheroids were then transduced with lentivirus (MAP4K4-1) in presence of polybrene (8 µg/ml) to knock down the expression of MAP4K4. After 2 days, puromycin selection (1 µg/µl) was added for 6 days. Clones were subcloned in a 96 multwell plate and DNA was extracted using the Proteinase K method. Targeted region was PCR amplified, and sequence for the detection of indels. Presence of indels was used as inclusion criteria for HGK protein expression analysis assessed by Western-blot using HGK antibody followed by a secondary antibody conjugated to HRP.

**Cell proliferation and viability assays.** Cell proliferation was assessed by cell counting manually using a hemocytometer. Briefly, cells were seeded onto 24-well plates (5 × 104 cells/well in 1000 µl of DMEM supplemented with 10% FBS). After 24, 48, or 72 h, cells were collected by trypsinization and counted using an inverted microscope. Non-viable cells were discriminated by trypan blue positive staining (0.1% Trypan Blue solution Sigma-Aldrich). Number of cells was normalized by initial number of total cells seeded. Cell viability was assessed by the MTS assay (CellTiter 96® Aqueous One solution cell proliferation assay, Promega). For the MTS assay, cells were seeded onto 96-well plates (1 × 104 cells/well in 100 µl of DMEM supplemented with 10% FBS). MTS was added after 24, 48, or 72 h, and absorbance was measured at 490 nm.

**Gene silencing by siRNA.** siRNAs were obtained from Dharmacon (siMAP4K4 ON-TARGETplus SAMRT POOL L-003971–00-0005). Non-targeting control siRNAs were obtained from Dharmacon (D-001810–01-20). 5 × 104 were initially transfected using Lipo- RNAiMAX with 25 nM of siRNA in suspension. After 24 h of incubation, adherent cells were resuspended again and re-transfected with 25 nM siRNA in suspension using Lipo- RNAiMAX following the instructions provided for the manufacturer.

**Immunofluorescence staining.** Cells were maintained on cover-glass objects coated with gelatine (0.2%) to 37 °C. They were fixed with paraformaldehyde (4%) for 20 min and permeabilized afterwards with Triton × 100 (0.3% PBS). Non-specific interactions were blocked by incubating cells 1 h in a BSA solution (1% in PBS). Subsequently, the cells were incubated in darkness with phalloidin conjugated with rhodamine-123
HGK is upregulated in metastatic prostate cancer cell lines. In order to shed some light on the role of HGK in metastasis and dissemination we decided to investigate its function on the invasive and migratory properties of PCa. First, we obtained publicly available RNA-seq data from 537 prostate adenocarcinoma (PRAD) patients from The Genome Cancer Atlas (TCGA) database. We compared MAP4K4 mRNA expression levels between normal and tumoral samples and between primary tumor and metastatic samples and showed that MAP4K4 levels were upregulated in the metastatic PCa samples as compared to primary tumor and normal tissue. TCGA data results were further supported by other four independent datasets (Grasso, Lapointe, Taylor and Varambally) (Fig. 1A). Our data base analysis suggested a positive correlation between MAP4K4 expression and PCa dissemination. To validate these results and establish the importance of MAP4K4 function in PCa cell motility, we analyzed the expression of MAP4K4 in 4 different metastatic prostate cancer cell lines, LNCaP, 22rv1, PC3 and DU145. As shown in Fig. 1B, MAP4K4 mRNA levels were upregulated in the highly metastatic cell lines, PC3 and DU145, compared to the low metastatic cell lines LNCaP and 22rv1. Thus, we analyzed HGK protein levels in the same cell lines and observed that HGK protein levels were higher in the highly metastatic PCa cells compared to low invasive cells (Fig. 1C), being PC3 cells those with a higher expression.

HGK depletion or inhibition decreases tumor cell migration and adhesion. To assess whether HGK upregulation was involved in the invasive properties of PCa cells, we decided to deplete HGK in the highly metastatic cell line PC3 using CRISPR approaches. HGK protein expression was efficiently depleted in two clones (HGK-KO-1 and 2) (Fig. 2A and supplementary Figure 1A and 1B), while non-targeting control (NTC) sgRNA had no effect on HGK levels. First, we evaluated the effect of HGK depletion in PCa cell lines on migration and adhesion. For migration characterization, we used transwell assays and found that migration was reduced in HGK-KO-1 and -2 cells as compared to NTC control cells, in response to FBS, used as chemotactictractant (Fig. 2B). To ensure that the impaired migratory phenotype was not dependent on the transwell assay, we performed wound healing assays with the same cellular model. In agreement with our previous results, the motility and ability to close the wound of HGK depleted cells was reduced compared to NTC control cells (Fig. 2C). Additionally, to avoid proliferation interferences, wound closure assay after mitomycin treatment was performed, showing similar results in HGK depleted cells (Supplementary Figure 2).

To prove that the impaired migration phenotype was not a consequence of the genetic edition, we performed two different approaches, transient HGK silencing in PCa cells using specific siRNAs and inhibition with a pharmacological inhibitor (PF 06260933 dihydrochloride). As expected, after downregulating HGK expression (Fig. 2D), PC3 migration decreased (Fig. 2E). HGK protein expression was efficiently downregulated, while the pharmacological inhibitor (PF 06260933 dihydrochloride). As expected, after downregulating HGK expression two different approaches, transient HGK silencing in PCa cells using specific siRNAs and inhibition with a different pharmacological inhibitor (PF 06260933 dihydrochloride), showed similar results in HGK depleted cells (Supplementary Figure 2).

Since HGK regulates cellular functions that control cell adhesion, a process highly connected with the migratory process, we decided to analyze the impact of HGK depletion on the adhesive properties of PCa cells. As shown in Fig. 2H, the number of adhered cells was decreased in cells with HGK down-regulation compared to NTC cells (Fig. 2H, right panel top). Interestingly, we observed that cell morphology was different, so we decided, not only to analyze cell adhesion, but also evaluate the cell spreading. To assess the extent and dynamics of these processes, we analyzed the ratio of actin cytoskeleton vs nuclei area by comparing Phalloidin/DAPI staining of seeded cells on gelatin-coated coverslips. As shown in Fig. 2H, the spread ratio increases dramatically 1 h after cell seeding in HGK depleted cells, suggesting that their adhesion required more time. However, the spreading process is improved along the time, leading to a more stable adhesion, which might impede migration. Thus, loss of HGK function drives a transition of PCa cells towards a non-migratory state. Taken together, these findings indicate that HGK inhibition reduces the migratory capacity of PCa cells.
HGK depletion alters tumorigenic properties of prostate cancer cells. HGK is known to mediate proliferation in T cells and a number of cancer cells, such as lung and gastric cancer. Therefore, we decided to study the effect of deleting HGK on the growth and tumorigenic properties of PC3 cells by performing several functional studies. First, we found that cell proliferation and viability were decreased in HGK depleted cells after 48 or 72 h (Fig. 3A). A cell cycle analysis by flow cytometry showed no statistically significant differences between HGK depleted and non-depleted cells, when cells are maintained in the presence of serum. However, in serum deprived cells, HGK pharmacological inhibition and HGK depletion significantly decrease S and G2/M phases leading to the accumulation of cells in G1 (Fig. 3B). In agreement with this result, anchorage-dependent and –independent growth assays revealed a decreased number of foci upon HGK depletion in PCa cells as compared to NTC cells (Fig. 3C,D).

The migration of human cancer cells is highly dependent on extracellular matrix and stromal cellular constituents, supported by engagement of different molecular machinery of migration in 2D versus 3D tissue architectures. We sought to determine the efficacy of HGK inhibition using the sprouting assay to assess 3D tumor growth and scattering of PCa cells. PC3-NTC cells manifest enhanced sprouting capacity compared to HGK depleted cells, as measured by the number of sprouts and the sprout length in the three-dimensional spheroid sprouting assay conducted in the presence of Matrigel matrix (Fig. 3E). Hence, our results suggest that HGK promotes PCa cells proliferation. Furthermore, it also induces PCa cells sprouting in 3E, suggesting HGK also promotes invasion in PCa cells.

HGK regulates cell morphology and F-actin cytoskeletal organization. Since our results have shown that HGK regulates migration and invasion, and these two processes are regulated by actin dynamics, we decided to analyze cell morphology of PCa cells. Figure 4A shows that HGK depleted cells switch from a spindle shaped invasive state to a cobblestone-like resting state. This altered morphology was also detected in anchorage-dependent growth assays. In order to characterize this difference in morphology, cell spreading was quantified by measuring cell area 24 h after being seeded. HGK depleted PC3 cells clearly increased their cell territories over time, whereas the average of NTC cell area remained unchanged. Interestingly, HGK pharmacological inhibition confirmed the results, so that treated cells had a higher mature spread ratio than untreated cells (Fig. 4B).

Since the cell morphology is directly influenced by the intracellular actin cytoskeleton, we study if HGK depletion affected F-actin organization. As shown in Fig. 4A, a closer analysis of HGK depleted cells exhibit some differences in their F-actin content and organization, compared to PC3-NTC. PC3-NTC showed a higher amount of parallel actin fibers, which dictates a fibroblast-like morphology. In contrast, HGK depleted cells contained more stress fibers and FA and less parallel actin fibers than PC3 NTC (Fig. 4A,B).
HGK regulates ruffles formation, cell motility and dissemination of PCa cells in response to TNF-α. The identification of downstream signaling mediators of HGK is crucial for understanding the mechanisms underlying HGK regulation in PCa metastasis to the bone. The bone marrow is a common and ideal destination for metastases. It contains sinusoidal vasculature, which is beneficial for circulating cancer cell migration. Bone marrow turnover and activity involves the production of numerous cytokines that co-incidentally can also attract and support metastatic PCa cells. TNF-α is a cytokine commonly found in bone marrow and one of the main known activators of HGK. It is also a strong mediator for PCa development and generation of metastasis. To test the role of HGK in TNF-α signaling we compared the activation status of JNK1/2 and p38...
MAPKs in PCa NTC or HGK depleted cells in response to TNF-α (Fig. 5A). As expected, depleted cells failed to activate JNKS and p38 MAPKs in response to TNF-α (Fig. 5A), while no differences were detected in the activation of ERKs (supplementary Fig. 3). These results suggest that HGK might mediate TNF-α effects through regulation of JNK1/2 and p38 MAPKs in prostate cancer metastasis. We also analyzed the migratory properties of PCa by using TNF-α as a chemoattractant stimulus and found that migration was strongly reduced in depleted cells as compared to NTC control cells (Fig. 5B). In agreement with this result, the treatment with HGK inhibitor displayed a similar effect than its genetic deletion (Fig. 5B). Furthermore, TNF-α induces a substantial reorganization of actin cytoskeleton and focal adhesions in epithelial cells\(^25\) and strongly mediates tumor dissemination in PCa cells\(^26\). Thus, we decided to analyze if HGK was involved in the actin cytoskeleton reorganization in response to TNF-α, facilitating cell motility. We observed that TNF-α stimulation induced a proper formation of dorsal arcs and ventral stress fibers with a strong cortical ring, characteristic of migratory cells. In contrast, KO cells organization was completely different with absence of a cortical ring and presence of a perinuclear actin cap (Fig. 5C and supplementary figure 5).

In order to investigate the molecular mechanism by which HGK regulates the actin cytoskeleton and FA, we analyzed the phosphorylated status of one of the main regulators, the focal adhesion kinase (FAK). FAK is a crucial signaling component that is activated by numerous stimuli and functions as an integrator that controls cell motility. It exerts its activity by influencing the cytoskeleton, the structure of cell adhesion sites, as well as membrane protrusions. FAK autophosphorylation on Y397 residue has been linked to maximum adhesion levels, and it is lost upon cell detachment. Additionally, Y397 phosphorylation is essential for development of mature FA. The distribution of vinculin, a main component of the mature focal adhesion complex, was also altered in HGK depleted cells. HGK-KO cells displayed a cytoplasmic dotted distribution of vinculin, usually associated with mature FAs, while in NTC cells vinculin expression was more disperse and concentrated in proximity to the nucleus (Supplementary figure 4). Figure 5D shows that depleted cells display a higher level of FAK-Y397 than NTC cells under basal condition and in response to TNF-α stimulation. Interestingly, Y397 phosphorylation drops in NTC cells in response to TNF-α, probably favoring FA turnover, cell spreading and migration, while HGK depleted cells fail to respond to TNF-α, leading to an aberrant regulation of FA dynamics, reduced migration and invasion.

High levels of HGK predict a poor prognosis in PCa patients. To further explore the role of this kinase in the metastatic process of prostate cancer in patients, we analyzed the association of HGK with cancer recurrence. High expression of the tumor biomarker PSA measured in blood samples is usually the first sign of tumor relapse, a surrogate marker for metastatic spreading. Kaplan–Meier method was used to compare biochemical recurrence (BCR)-free survival of patients with high and low MAP4K4 expression as described in material and methods. MAP4K4 mRNA expression across all PCa tissues was used to classify all cases into high (n = 167) and low HGK expression (n = 246). Figure 6A shows that patients with high expression of HGK show shorter BCR-free survival (HR 3.65, CI 2–6.63, p = 5.8e–06) compared with those with low expression. Additionally, we analyzed the BCR-free survival in hormone resistant patients. These patients have developed resistance to hormone therapy, a hallmark of the evolution to castration resistant prostate cancer. Figure 6B shows that hormonal-treated PCa patients with high expression of HGK showed shorter BCR-free survival (HR 5.63, CI 1.58–20.06, p = 0.0027) compared to those with lower expression. We also analyzed the expression levels of MAP4K4 in hormone resistant patients. As it can be seen in Fig. 6C, and consistent with our previous results, MAP4K4 expression was higher in hormonal therapy resistant PCa patients than sensitive.

Discussion
Several efforts have been made to characterize PCa tumor development. Correspondingly, there is a more comprehensible idea of the genes and signaling beneath this process than the understanding of the PCa metastatic process. Consequently, there are several therapeutic strategies for PCa tumors that remain effective in less
aggressive states and as a result the disease in patients diagnosed early has a good prognosis. However, the picture is completely different for metastatic PCa. There is still no effective treatment for this stage of the disease and hence, there is an urgent need to find key gene regulators of this process, to be used as both, prognosis biomarkers and more importantly, therapeutic targets that could improve metastatic PCa survival rate. Our findings point out to HGK, a MAPK family member, as a critical regulator of PCa tumor progression and its implication in regulating focal cell adhesion signaling.
Our results showed that HGK levels were lower in benign prostate cells than in PCa cells. In fact, the hormone-independent and highly invasive PC3 PCa cell line exhibited the highest HGK protein levels. These findings indicated that HGK upregulation correlates with human PCa stages. HGK has been widely associated with the development of epithelial cancers. Its upregulation was associated with poor patient prognosis in colorectal cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, lung adenocarcinoma and prostate cancer. In addition, HGK protein levels were elevated in lung adenocarcinoma, pancreatic cancer, prostate cancer, brain and kidney tumors and glioblastoma. Numerous laboratories underscored important roles for HGK in cell proliferation and invasion in other cellular models. For example, high levels of MAP4K4 mRNA expression augmented proliferation and invasion in ovarian cancer and medulloblastoma.

We found that a high MAP4K4 expression correlates with an enhanced proliferation and tumorigenic abilities of PCa cells and its depletion strongly downregulates these processes in vitro assays. Hence, HGK seems to play an important role in PCa tumor progression by promoting tumorigenesis and dissemination. In agreement with our results, there is a growing body of evidence for the involvement of HGK in cancer cell migration and invasion. Former screenings for positive modulators of tumor cellular motility identified HGK in glioblastoma, ovarian cancer and prostate cancer cell lines. Despite the several evidences of association, the specific underlying mechanisms through which HGK influences invasion are not yet understood. For example, Miao et al. proposes that HGK acts through an upregulation of Myc oncogene. Collins et al. indicates that HGK signals through JNK in an ovarian carcinoma cell line. Gao et al. points out to the upregulation of MAPKs in lung adenocarcinoma and Prolo et al. suggests that HGK promotes an EMT reprogramming in glioblastoma. Protein function often depends on tissue expression and/or tumor type, but the disparity of mechanisms proposed for HGK reflects a lack of knowledge of its biology. Interestingly, none of the previous work studied the relation between HGK and cytoskeleton regulation.

According to our data, HGK depletion induces a strong modification of the actin cytoskeleton, altering the shape and morphology, as well as the area influenced by the cell. This altered morphology and shape has also been observed in other studies with other cellular models after HGK depletion or inhibition. Our results agree with Yue et al. observations in his conditional HGK KO mouse model, which displays an impaired migration and altered morphology of non-tumor cells (keratinocytes) as a consequence of a disorganized actin cytoskeleton. Additionally, Yue’s HGK mouse model showed that HGK promotes FA dynamics by regulating IQSEC1/Arf6 pathway, controlling internalization and endocytosis of integrin in endothelial cells. FAs are assembled at ECM–integrin junctions linking cytoskeletal and signaling proteins, such as Abl, Src, and Focal Adhesion Kinase (FAK), controlling cell adhesion, spreading and migration. We observed a similar effect to the one observed by Yue et al., either by genetic ablation or pharmacological inhibition of HGK in PCa. Our results showed that HGK, not only increases the ability of the cells to quickly adhere, but also decreases the cell spreading process and promotes migration in response to TNF-α and other cytokines most likely through actin cytoskeleton regulation. Several evidences suggest that HGK regulates cytoskeleton and cell adhesion to matrix via FA disassembly and FA–actin stability through Arf6 activation. In addition, phosphorylation of ERM proteins and Arp2 provides another mechanism for HGK-induced actin filament nucleation and lamellipodium formation in response to EGFR activation. More importantly, here we also show that HGK depletion reduces adhesion, while increasing cell spreading probably through FAs stabilisation, impairing cell migration. As previously reported, FAK activity is essential to regulate the FA dynamics, characterized by continual bouts of formation, maturation and disassembly. FAK autophosphorylation on Y397 residue is essential for its association with Src and it has been linked to adhesion and FAs turnover. FAK ability to promote both the maturation and turnover of focal contacts is related to its dual role as a signaling kinase and an adaptor/scaffold protein. This ability places FAK as a dual modulator, able to regulate not only adhesion, but also migration. Our analysis show that HGK depleted cells display higher levels of the autophosphorylated Y397-FAK residue than NTC cells in response to TNF-α stimulation, as well as an increase of the immunoreactivity to vinculin suggesting a higher number of mature FAs. This higher phosphorylation is observed also under basal condition. Interestingly, Y397 phosphorylation drops in TNF-α treated NTC cells favoring FA turnover by accelerating the disassembly of mature FA and promoting the formation of nascent FA. This process will favor cell migration in response to TNF-α. On the contrary, HGK depleted cells response to TNF-α leads to aberrant regulation of FA dynamics, resulting in a less migratory phenotype (Fig. 6D). Moreover, TNF-α increases the activation of different signaling pathways, including FAK phosphorylation in HGK depleted cells. This response indicates that HGK could regulate the phosphorylation of FAK indirectly. Additional signaling pathways could contribute to this effect such as the wnt pathway, a known mediator of PCa steneness and metastasis that can be modulated by TNF-α.
Figure 4. HGK depletion alters cell actin cytoskeleton organization. (A) Top left panel, Phase-contrast microscopy images of NTC and HGK depleted PC3 cells maintained in the presence of 10% FBS for 24 h. Top Right panel, Immuno-fluorescence microscopy images of phalloidin staining (red) in NTC and HGK depleted PC3 cells. Cell nuclei were stained with DAPI (blue). Scale bars: 75 μm. An amplification of images is depicted. (B) Adhesion analysis at 24 h in indicated cells. Left panels, representative images of adhered PC3 cells. Right top panels, histograms showing the mean value ± S.E.M. of the percentage of adhered cells referred to non-silenced cells at 24 h (n = 3). Right bottom panel, histograms showing the mean value ± S.E.M. of the ratio cytosol/nucleus referred to untreated cells at 24 h.
Figure 5. HGK regulates ruffle formation and cancer cell motility in response to TNF-α. (A) Representative Western-blot analysis of the phosphorylated levels of JNKs and p38 proteins normalized with β-actin on the indicated PC3 cells. Serum-starved cells (for 16 h) were stimulated with TNF-α for 15 min or maintained untreated. Densitometric quantification are shown (B) Migration analysis of the indicated PC3 cell using TNF-α as chemoattractant. Left panels, representative images of migrating cells (bars: 100 µm); right panels, histograms showing the mean value ± S.E.M. of the number of migrating cells (n = 3). (C) Immuno-fluorescence microscopy images of phalloidin staining (red) in NTC and HGK depleted PC3 cells. Serum starved cells were stimulated with TNF-α for 15 min. Cell nuclei were stained with DAPI (blue). Scale bars: 150 and 75 µm. Right panel, histograms showing the mean value ± S.E.M. of cells with ruffles referred to non-silenced cells (n = 3). (D) Representative western-blot analysis of phosphorylated levels of JNKs and FAK-Y397 normalized with β-actin. Serum-starved PC3 cells (for 16 h) were stimulated with TNF-α for 15 min or maintained untreated. Full-length blots are presented in Supplementary Figure 3.
Hence, the disturbance of F-actin via GSK-3β inhibition leads to a decreased stemness and bone metastasis in prostate cancer. Preliminary data (not shown) from our lab indicates that HGK depleted cells failed to activate ATF2 in response to WNT5A, although further analyses are needed to characterize the potential implication of HGK in this pathway.

Finally, we found that MAP4K4 expression at both mRNA and protein levels were up-regulated in PCa cells at advanced pathological or clinical stages, being identified as an unfavorable prognostic factor of BCR-free survival in PCa. Furthermore, our results show that high MAP4K4 expression is dramatically associated with aggressive tumor progression in patients with PCa, short overall survival time and short BCR-free survival time.

In conclusion, our data strongly suggest that HGK upregulation may play a pivotal role in the characteristics and aggressive behaviour of PCa, especially in groups with advanced pathological disease. Furthermore, our results showed that HGK increases the migratory capacity, loss of adherence and proliferation and survival.

Figure 6. High levels of HGK predict a poor prognosis in PCa patients. (A) Kaplan–Meier curves showing the difference in BCR-free survival between patients with high and low expression levels of MAP4K4. (B) Kaplan–Meier curves showing the difference in BCR-free survival between hormonal-therapy treated patients with high and low expression levels of MAP4K. (C) MAP4K4 expression in hormonal-therapy resistant and sensitive PCa patients (TCGA, n=32). (D) Schematic summarizing of the regulation of Focal Adhesion (FA) turnover and its impact on cellular motility by HGK.
abilities of the PCa cells analyzed. Loss of HGK function drives prostate cancer cells into a non-invasive state, suggesting that HGK is required for the maintenance of the malignant phenotype of metastatic prostate carcinoma. Additionally, our findings indicate that HGK upregulation is associated with poor prognosis in patients with PCa pointing to HGK as a new bad prognosis biomarker that could be also used to distinguish patients with aggressive PCa. Although further studies will be necessary to gain a full understanding of the underlying molecular mechanisms, we have shown that its pharmacological inhibition could be an effective therapeutic approach to target prostate carcinoma in combination with other interventions.

Data availability
All data is available upon request.

Received: 24 November 2020; Accepted: 19 May 2021
Published online: 10 June 2021

References
1. Albala, D. M. Imaging and treatment recommendations in patients with castrate-resistant prostate cancer. Rev. Urol. 19, 200–202. https://doi.org/10.3909/rui393PracticeProfile (2017).
2. Weiner, A. B., Mattulewicz, R. S., Eggenger, S. E. & Schaeffer, E. M. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 19, 395–397. https://doi.org/10.1038/jpca.2016.30 (2016).
3. Gutierrez-Uzquiza, A., Lopez-Haber, C., Jernigan, D. L., Fatatis, A. & Kazanietz, M. G. PKCε is an essential mediator of prostate cancer bone metastasis. Mol. Cancer Res. 13, 1336–1346. https://doi.org/10.1158/1541-7786.MCR-15-0111 (2015).
4. Faltermeier, C. M. et al. Functional screen identifies kinases driving prostate cancer viscerol and bone metastasis. Proc. Natl. Acad. Sci. U. S. A. 113, E172-181. https://doi.org/10.1073/pnas.1521674112 (2016).
5. Tesz, G. J. et al. Tumor necrosis factor alpha (TNFalpha) stimulates MAP4K4 expression through TNFalpha receptor 1 signaling to c-Jun and activating transcription factor 2. J. Biol. Chem. 282, 19302–19312. https://doi.org/10.1074/jbc.M700665200 (2007).
6. Collins, C. S. et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc. Natl. Acad. Sci. U. S. A. 103, 3775–3780. https://doi.org/10.1073/pnas.0600040103 (2006).
7. Wright, J. H. et al. The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol. Cell. Biol. 23, 2068–2082. https://doi.org/10.1128/mcb.23.6.2068-2082.2003 (2003).
8. Gao, X. et al. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. Mol. Oncol. 11, 628–639. https://doi.org/10.1002/1878-0261.20557 (2017).
9. Zhao, G. et al. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol. Cancer Ther. 12, 2569–2580. http://implants.2013.stjames.93 (2013).
10. Liu, A. W. et al. SHRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin. Cancer Res. 17, 710–720. https://doi.org/10.1158/1078-0432.CCR-10-0331 (2011).
11. Hao, J. M. et al. A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J. Pathol. 220, 475–489. https://doi.org/10.1002/path.2668 (2010).
12. Liang, J. J. et al. Expression of MAP4K4 is associated with worse prognosis in patients with stage II prostate ductal adenocarcinoma. Clin. Cancer Res. 14, 7043–7049. https://doi.org/10.1158/1078-0432.CCR-08-0381 (2008).
13. Qiu, M. H. et al. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol. Res. Pract. 208, 541–548. https://doi.org/10.1016/j.prp.2012.06.001 (2012).
14. Bai, Z., Yao, Q., Sun, Z., Xu, F. & Zhou, J. Prognostic value of mRNA expression of MAP4K family in acute myeloid leukemia. Technol. Cancer Res. Treat. 18, 3153033819873927. https://doi.org/10.1177/1533033819873927 (2019).
15. Tripolitsioti, D. et al. MAP4K4 controlled integrin beta1 activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells. Oncotarget 9, 23220–23236. https://doi.org/10.18632/oncotarget.25294 (2018).
16. Loftus, J. C. et al. A novel interaction between Pyk2 and MAP4K4 is integrated with glioma cell migration. J. Signal. Transduct. 2013, 956580. https://doi.org/10.1155/2013/956580 (2013).
17. Yue, J. et al. Microtubules regulate focal adhesion dynamics through MAP4K4. Dev. Cell 31, 572–585. https://doi.org/10.1016/j.devcel.2014.01.025 (2014).
18. Miao, W., Yuan, J., Li, L. & Wang, Y. Parallel-reaction-monitoring-based proteome-wide profiling of differential kinase protein expression during prostate cancer metastasis in vitro. Anal. Chem. 91, 9893–9900. https://doi.org/10.1021/acs.analchem.9b01561 (2019).
19. Prollo, L. M. et al. Targeted genomic CRISPR-Cas9 screen identifies MAP4K4 as essential for glioblastoma invasion. Sci. Rep. 9, 14020. https://doi.org/10.1038/s41598-019-50160-w (2019).
20. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402–408. https://doi.org/10.1006/meth.2001.1262 (2001).
21. Huang, H. et al. MAP4K4 deletion inhibits proliferation and activation of CD4(+ ) T cell and promotes T regulatory cell generation in vitro. Cell. Immunol. 289, 15–20. https://doi.org/10.1016/j.cellimm.2014.02.006 (2014).
22. Liu, Y. F. et al. Silencing of MAP4K4 by short hairpin RNA suppresses proliferation, induces G1 cell cycle arrest and induces apoptosis in gastric cancer cells. Mol. Med. Rep. 13, 41–48. https://doi.org/10.3892/mmr.2015.4510 (2016).
23. Bussard, K. M., Gay, C. V. & Mastro, A. M. The bone microenvironment in metastasis: what is special about bone?. Cancer Metastasis Rev. 27, 41–55. https://doi.org/10.1007/s10555-007-9109-8 (2008).
24. Yao, Z. et al. A novel human STE20-related protein kinase, HGK, that specifically activates the c-Jun N-terminal kinase signaling pathway. J. Biol. Chem. 274, 2118–2125. https://doi.org/10.1074/jbc.M700665200 (1999).
25. Koukouritaki, S. B. et al. TNF-alpha induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase. Mol. Med. 5, 382–392 (1999).
26. Tse, B. W., Scott, K. F. & Russell, P. J. Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer 2012, 128965. https://doi.org/10.11522/128965 (2012).
27. Rizzardi, A. E. et al. Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer 14, 244. https://doi.org/10.1186/s12890-014-1424-4 (2014).
28. Santhanam Kumar, K. et al. The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma. Springerplus 4, 19. https://doi.org/10.1186/s40064-015-0784-2 (2015).
29. Panetti, T. S. Tyrosine phosphorylation of paxillin, FAK, and p130CAS: effects on cell spreading and migration. Front. Biosci. 7, d143-150 (2002).
30. Dumpy, J. L. et al. The Arf6 GEF GEP100/BRAG2 regulates cell adhesion by controlling endocytosis of beta1 integrins. Curr. Biol. 16, 315–320. https://doi.org/10.1016/j.cub.2005.12.032 (2006).
31. Hiroi, T., Someya, A., Thompson, W., Moss, J. & Vaughan, M. GEP100/BRAG2: activator of ADP-ribosylation factor 6 for regulation of cell adhesion and actin cytoskeleton via E-cadherin and alpha-catenin. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 10672–10677. [https://doi.org/10.1073/pnas.0604091103](https://doi.org/10.1073/pnas.0604091103) (2006).

32. Morishige, M. et al. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. *Nat. Cell Biol.* **10**, 85–92. [https://doi.org/10.1038/ncb1672](https://doi.org/10.1038/ncb1672) (2008).

33. Someya, A., Moss, J. & Nagaoka, I. The guanine nucleotide exchange protein for ADP-ribosylation factor 6, ARF-GEP100/BRAG2, regulates phagocytosis of monocyte phagocytes in an ARF6-dependent process. *J. Biol. Chem.* **285**, 30698–30707. [https://doi.org/10.1074/jbc.M110.107458](https://doi.org/10.1074/jbc.M110.107458) (2010).

34. LeClaire, L. L., Rana, M., Baumgartner, M. & Barber, D. L. The Nck-interacting kinase NIK increases Arp2/3 complex activity by phosphorylating the Arp2 subunit. *J. Cell Biol.* **208**, 161–170. [https://doi.org/10.1083/jcb.201404095](https://doi.org/10.1083/jcb.201404095) (2015).

35. Schaller, M. D. Biochemical signals and biological responses elicited by the focal adhesion kinase. *Biochim. Biophys. Acta* **1540**, 1–21. [https://doi.org/10.1016/S0167-4889(01)00123-9](https://doi.org/10.1016/S0167-4889(01)00123-9) (2001).

36. Seetharaman, S. & Etienne-Manneville, S. Cytoskeletal crosstalk in cell migration. *Trends Cell Biol.* **30**, 720–735. [https://doi.org/10.1016/j.tcb.2020.06.004](https://doi.org/10.1016/j.tcb.2020.06.004) (2020).

37. Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. *Nature* **434**, 843–850. [https://doi.org/10.1038/nature03319](https://doi.org/10.1038/nature03319) (2005).

38. Qadir, A. S. et al. Msx2 is required for TNF-alpha-induced canonical Wnt signaling in 3T3-L1 preadipocytes. *Biochim. Biophys. Res. Commun.* **408**, 399–404. [https://doi.org/10.1016/j.bbrc.2011.04.029](https://doi.org/10.1016/j.bbrc.2011.04.029) (2011).

Acknowledgements

We thank Dr. G. Velasco UCM for his kind donation of research material and Dr. Javier Fernández Ruiz UCM for assistance with the immunofluorescent microscope.

Author contributions

S.G.-G., M.R.-F., N.F., S.M., B.G., A.O., P.B., A.P. and A.G.-U. designed the experiments. S.G.G., M.R.-F., N.F., S.M., B.G., P.B. and A.G.-U. carried out the experiments and analysis of the databases. S.G.-G., M.R.-F., N.F., S.M., B.G., A.O., P.B. and A.G.-U. analyzed the data. M.R.-F., P.B., A.P. and A.G.-U. wrote the manuscript. S.G.-G., M.R.-F., N.F., S.M., B.G., A.O., P.B. and A.G.-U. provided feedback. All authors read and approved the manuscript.

Funding

This work was funded by Comunidad de Madrid under project “genome-scale screening to identify and validate novel genes essential for prostate cancer metastasis” 2017-T1/BMD-5468 and Spanish Government Grants (SAF2016-76588-C2-1-R and PID2019-104143RB-C22 and PID2019-104991RB-I00). B. Győrffy research was financed by the 2018-2.1.17-TET-KR-00001 and 2018-1.3.1-VKE-2018-00032 grants and by the Higher Education Institutional Excellence Programme (2020-4.1.1.-TKP2020) of the Ministry for Innovation and Technology in Hungary, within the framework of the Bionic thematic programme of the Semmelweis University.

Competing interests

The authors declare no competing interests.

Additional information

The online version contains supplementary material available at [https://doi.org/10.1038/s41598-021-91292-2](https://doi.org/10.1038/s41598-021-91292-2).

Correspondence and requests for materials should be addressed to A.G.-U.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021